KRAS and adrenal cortex neoplasm: Since the target genes on the chip were originally selected from a microarray which had been used to distinguish between adrenocortical tumor tissues with mutant KRAS and normal controls[19], and since the detection accuracy was validated as 93.85% in that study, the chip is reasonably referred to as KRAS detection chip.